An official website of the United States government
A .mil website belongs to an official U.S. Department of Defense organization in the United States.
A lock (lock ) or https:// means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.

DGMC offers innovative technology for treating cancerous tumors

  • Published
  • 60th Medical Group
TRAVIS AIR FORCE BASE,Calif. --  David Grant USAF Medical Center hosted a Grand Opening of new services within the Joint Radiation Oncology Center March 25. A partnership between the Department of Defense and Department of Veterans Affairs, the JROC at DGMC showcases the latest cutting-edge medical technology in Solano County for treating cancerous tumors and lesions with pinpoint precision and accuracy.

"Image guided radiation therapy and intensity modulated radiation therapy are two of the newest innovations in fighting cancer with a single machine," said Col. (Dr.) Roland Engel, 60th Medical Operations Squadron Radiology Oncology flight commander. "DGMC becomes one of only a handful of medical centers in the northern California region to offer RapidArc™, one of the most advanced and efficient methods for delivering cancer-fighting treatment to our patients."

According to Doctor Engel, the Clinac® IX and Trilogy™ linear accelerators allow a radiation dose to conform more precisely to the three-dimensional shape of the tumor. Clinicians are able to adjust the patient's position to ensure precise target of the tumor, thereby sparing surrounding tissues to the greatest extent possible.

"Our new machines will allow us to deliver even higher does to tumors, without overexposing nearby normal or critical structures," said Capt. (Dr.) Borislav Hristov, 60 MDOS staff radiation oncologist.

"The addition of this advanced technology enables us to treat more patients in less time. Treatments that normally took 10 to 15 minutes now take five to ten minutes," explained Doctor Hristov. "In some cases, we now have the ability to eradicate the tumor in a few visits versus the traditional five to eight weeks. We are very excited about being able to give our patients the best treatment available."